Answers are grounded in this paper and cite their sources.
Background: A well-functioning arteriovenous fistula (AVF) is vital for effective haemodialysis (HD). Delays in AVF creation and maturation prolong central venous catheter (CVC) use, increasing the risk of complications. By achieving earlier AVF maturation, we may shorten the CVC dwelling time and reduce risk of CVC complications. This study evaluated the effect of Far Infrared Therapy (FIRAPY) on promoting early AVF maturation at 4 weeks. Methods: This prospective, open-labelled, randomized controlled trial was conducted at Universiti Malaya Medical Centre, Malaysia. Ninety-seven patients with end-stage renal disease (ESRD) with new AVFs were randomized into treatment (n = 49) and control (n = 48) groups. The treatment group received FIRAPY for 40 minutes twice daily for 1-month post-creation. The primary outcome was early AVF maturation at 4 weeks, defined as (1) access blood flow >500 ml/min, (2) venous limb diameter ≥6 mm in brachiocephalic fistula (BCF) or ≥5 mm in radiocephalic fistula (RCF), (3) venous depth <6 mm, and (4) successful cannulation for three consecutive HD sessions. Secondary outcomes were unassisted AVF patency at 6 months and CVC complication rates. Results: The FIRAPY group showed significantly higher 4-week AVF maturation (69.4% vs 39.6%, p = 0.003) and lower CVC complications (27.1% vs 82%, p = 0.014). Although 6-month unassisted patency did not differ significantly (65.3% vs 52.1%, p = 0.219), the treatment group demonstrated lower primary failure (10.2% vs 29.2%, p = 0.019) and higher overall maturation (89.8% vs 70.8%, p = 0.019). Conclusion: FIRAPY enhances early AVF maturation, reduces catheter-related complications, and lowers primary failure in ESRD patients on HD. Extended FIRAPY duration may further improve long-term patency outcomes.
No takes yet. Share an insight, caveat, or question.
Ahmad et al. (2026) studied this question.
Synapse has enriched 6 related papers. Consider them for comparative context: